Birt-Hogg-Dube´ (BHD) syndrome is an autosomal dominant multisystem disorder with skin (fibrofolliculomas or trichodiscomas), lung (cysts and pneumothorax) and kidney (renal cell carcinoma) tumours. Although colorectal neoplasia was reported initially to be part of the BHD phenotype, some recent studies have not confirmed this association. We undertook a 
INTRODUCTION
Colorectal cancer (CRC) is the third most common form of cancer in the USA and Europe. Genetic factors have an important role in the pathogenesis of CRC and may be implicated in about a third of cases [1] . The identification of genes for familial colorectal cancer not only enhances clinical management of at risk families but can also provide important insights into the pathogenesis of familial and sporadic forms of CRC. Thus germline mutations in the APC tumour suppressor gene cause familial adenomatous polyposis and the APC gene is somatically inactivated in >80% of sporadic CRC [2, 3] .
Similarly germline mutations in mismatch repair genes (most commonly MSH2, MLH1 and MSH6) are associated with Lynch syndrome (hereditary non-polyposis colon cancer syndrome (HNPCC)) which is characterized by the finding of microsatellite instability in colorectal polyps and tumours [4] . Defects in mismatch repair can contribute to cancer development by predisposing to somatic mutations in colorectal cancer suppressor genes that contain short repeat coding sequences [5] .
Monogenic forms of colorectal cancer such as familial adenomatous polyposis and Lynch syndrome account for up to 5% of all cases of CRC [6] . Whilst there has been considerable recent progress in the identification of common low penetrance colorectal cancer susceptibility alleles (see Houlston et al 2008 and references within [7] ), many cases of familial non-HNPCC clusters of colorectal cancer are unexplained. The delineation of additional inherited disorders associated with CRC susceptibility could lead to more accurate diagnosis of familial CRC and/or provide insights into molecular mechanisms of tumourigenesis in sporadic CRC.
Birt-Hogg-Dube´ (BHD) syndrome is a dominantly inherited familial cancer syndrome characterized by the development of benign skin tumours (fibrofolliculomas or trichodiscomas) on the face and upper body, pulmonary cysts and pneumothorax and renal cell carcinoma (RCC) (see [8] and references within). BHD syndrome is caused by mutations in the folliculin gene (FLCN) at 17p11.2 [9] [10] [11] [12] . More than 40% of germline FLCN mutations are accounted for by a hypermutable mononucleotide tract (C 8 ) in exon 11 [13, 14] . BHD displays variable expression and incomplete/age-dependent penetrance and is underdiagnosed. However, molecular genetic analysis enables a diagnosis of BHD to be made in individuals who do not satisfy clinical diagnostic criteria. Recently we detected previously unsuspected germline FLCN mutations in ~5% of patients with features of nonsyndromic inherited RCC (familial RCC, multiple tumours or early onset) [15] . BHD was described in 1977 and early reports suggested an association with colorectal neoplasia [16] [17] [18] [19] [20] [21] . However, in a large study of 111 BHD patients, Zbar et al 2002 found no association between BHD and colonic polyps or CRC [22] . Nevertheless, Khoo et al 2002 described a large family with BHD in which 6 of 20 affected individuals had developed colonic polyposis and two family members had died of probable gastrointestinal cancer [12] . These observations suggested that some BHD families are at increased risk of colorectal neoplasia and that interfamilial differences might be related to allelic heterogeneity or modifier effects.
Several studies have investigated the role of FLCN inactivation in colorectal tumourigenesis and somatic mutations in the exon 11 mononucleotide tract in CRC with microsatellite instability were identified in two studies [23, 24] . In order to further evaluate the potential role of folliculin in the pathogenesis of CRC we investigated (a) whether individuals with familial colorectal cancer of unknown cause might have germline FLCN mutations, (b) the genotype-phenotype correlations for CRC in BHD patients and (c) the frequency and clinicopathological associations of FLCN exon 11 mononucleotide tract mutations in microsatellite unstable CRC.
PATIENTS AND METHODS

Patients and samples
Three cohorts of patients were studied: (a) blood DNA samples from 50 unrelated patients with familial colorectal cancer and no evidence of familial adenomatous polyposis or germline mismatch repair gene mutations (ascertained for the CORGI study [25] ) were analysed for germline FLCN mutations; (b) clinical data for colorectal neoplasia (colorectal cancer and adenomatous polyps) status was collected from 149 affected patients (from 51 families) with BHD (either known to have a germline FLCN mutation, or if mutation negative, clinically affected according to European BHD Consortium diagnostic criteria [8] . 
Molecular Genetic Analysis
DNA was extracted from blood using standard methods and from paraffin embedded CRC samples using standard procedures [26] . FLCN mutation analysis was performed for all coding exons and exon-intron boundaries by PCR amplification and direct sequencing of the PCR products. Primer sequences are shown in Table 3 . To test for the presence of frameshift mutations in MSI tumour samples small range, specific PCR reactions were designed. Primer sequences are shown in Table 4 . PCR was performed in 50ul volumes using 20mM 
Statistical Analysis
Comparison of tumour characteristics for FLCN mutated and non-mutated sporadic colorectal cancer was undertaken using Fishers exact test. Comparison of age-related colorectal neoplasia risks in BHD patients was performed using Kaplan-Meier analysis and log rank testing. Statistical significance was taken at 5%. MSH6 mononucleotide tract mutations were detected in 7/30 (23%) of the colorectal cancers tested (28.5% and 8% respectively of those with and without MSH2 or MLH1 protein expression loss; P=0.17) ( Table 2) .
RESULTS
FLCN Mutation Analysis in
DISCUSSION
The cumulative lifetime risk of developing colorectal cancer in the USA is about 6% [27] . Assessing precise tumour risks in rare familial cancer syndromes is difficult because of limited number of patients available and possible ascertainment bias. We undertook a retrospective study and none of the colorectal tumours or polyps that were diagnosed in our series were detected as a result of screening asymptomatic individuals. Although the rsiks of colorectal cancer were higher than in a UK general population cohort (see Figure 1 ), much larger numbers of patients would be required to obtain statistically significant results and in order to obtain more definitive data on colorectal neoplasia risks in BHD syndrome, we plan to perform a prospective multinational study. However despite the limitations of the current study, it has provided several noteworthy findings. Firstly our results differ from those of Toro et al [28] who did not detect a colorectal neoplasm in 152 patients with BHD syndrome.
In a subsequent study, the same group reported 3 colorectal tumours in 111 patients with BHD syndrome, but concluded that this was not statistically significant and that there was not an increased risk of colorectal neoplasia in BHD [22] . Such findings contrast with those of Khoo et al who described a high risk of colorectal neoplasia in a large French family with BHD syndrome [12] . Difference in colorectal risk between different studies and families [11, 21, 27 ] might result from interfamilial differences in exposure to environmental or genetic modifier effects or FLCN allelic heterogeneity (i.e. different mutations in FLCN might be associated with differing risks of colorectal cancer). We found that BHD patients with an exon 11 mononucleotide tract mutation had a significantly higher risk of colorectal neoplasia than patients with a c.610_611delGGinsTA frameshift mutation. In addition, we note that the germline FLCN mutation in the high risk family described by Khoo et al (2002) also affected the exon 11 mononucleotide tract (c.1285delC (formerly known as c.1733delC). In the absence of nonsense-mediated mRNA decay the c.1285dupC and c.1285delC mutations would be predicted to result in a protein with p.His429ProfsX27( lacking 126 amino acids) and p.His429ThrfsX39 (lacking 114 amino acids) respectively. It could be hypothesised that, if p.His429ProfsX27 and p.His429ThrfsX39 are produced in colorectal cells, they might have a dominant negative effect on FLCN function that would not be associated with the c.610delGCinsTA mutation (this is predicted to result in a protein (p.Ala204X) lacking 377 amino acids). Alternatively, although both mutations would be predicted to result in proteins lacking the FNIP1 binding region, folliculin is likely to have multiple functions and so these might be differentially affected by the two different mutant proteins. Nevertheless, we note that 19 patients with exon 11 C 8 frameshift mutations described by Toro et al [14] did not develop colorectal neoplasia and further studies are required to confirm our genotypephenotype findings in a larger dataset.
Somatic inactivation of familial cancer genes can play a major role in the pathogenesis of sporadic tumours as exemplified by the finding of somatic mutations of APC and VHL in most colorectal and clear cell RCC respectively [29, 30] . In contrast, mutation analysis of FLCN has generally revealed a low frequency of mutations in colorectal cancer.
Thus in three studies in which the whole of the FLCN coding sequence was analysed in primary CRC the frequency of potential mutations (not involving the C 8 tract) was 0/9 CRC [23] , 2/29 CRC (germline p. Arg320Gln and somatic p. Arg392Gly missense substitutions) [24] and 2/30 microsatellite stable CRC (p.S79W and p.A445T) [31] . However none of the four missense variants detected have been identified as germline mutations in BHD patients [32] , and so the somatic changes may represent "passenger" rather than "driver mutations".
In view of our finding of an association between colorectal neoplasia risk and a germline c.1285dupC mutation, we proceeded to investigate further whether there might be a link between colorectal neoplasia and exon 11 mononucleotide repeat region mutations. Such (folliculin interacting protein 1), a poorly characterised protein that binds to 5' AMPactivated protein kinase (AMPK) [35] . It was also reported that FLCN phosphorylation was facilitated by FNIP1, and to be dependent on mTOR and AMPK activity, suggesting a functional relationship between FLCN/FNIP1 and mTOR/AMPK signalling and leading to suggestions that FNIP1 and FLCN may be downstream effectors of AMPK and mTOR, [35] .
However, the effect of FLCN inactivation on the mTOR pathway has varied between studies.
Thus whereas Baba et al (2006) found that a FLCN null RCC cell line has evidence of mTOR activation, Hartman et al (2009) reported lower levels of S6 (an indication of mTOR activity) in cysts and tumours from mice with targeted inactivation of the Bhd gene [36] . Dysregulation of the mTOR pathway has been linked to intestinal tumourigenesis as gastrointestinal polyposis occurs in Cowden syndrome [37] and rapamycin (an inhibitor of mTOR complex 1) therapy suppresses polyp formation in a mouse model of model for human familial adenomatous polyposis [38] . Nevertheless folliculin is likely to be implicated in the regulation of multiple signalling pathways and it may be that the risk of CRC in BHD is related to other pathways. Hence, in order to evaluate the possible functional basis of FLCN genotype-phenotype correlations, it will be necessary to first better characterise the function of the FLCN gene product.
Previously we identified clinically unsuspected germline FLCN mutations in individuals presenting with features of non-syndromic RCC [15] . However we did not identify any germline FLCN mutations in patients with features of non-syndromic CRC. This difference between the involvement of BHD in familial non-syndromic RCC and CRC may have several explanations. Firstly, because BHD is a rare disorder and familial CRC is more frequent than familial RCC it might be necessary to study a much larger group of familial CRC patients in order to identify cases with unsuspected BHD mutations. Secondly, whereas BHD is associated with early onset RCC the mean age of colorectal cancer in our BHD patient series was 57.4 years. Many clinical criteria for the diagnosis of familial CRC cancer risk include a bias for earlier onset tumours (e.g. the Amsterdam criteria for the diagnosis of HNPCC), which would seem to make it less likely that BHD patients might present in this group. As older patients with BHD are more likely to have fibrofolliculomas (enabling a clinical diagnosis of BHD), we suggest that in the absence of a previous medical history or family history of BHD-associated clinical features, the frequency of BHD in patients with features of inherited CRC susceptibility is likely to be very low and FLCN mutation analysis is not indicated. The detection of a genotype-phenotype correlation for colorectal neoplasia risk in BHD provides a potential explanation for the reported heterogeneity in colorectal neoplasia risk in BHD. Although further studies are required to confirm and extend the correlation between FLCN mutation type and colorectal neoplasia risk, our findings suggest that when colorectal neoplasia does occur in BHD it does not occur at a very early age. If our findings are confirmed then mutation type might be used to determine CRC risk in BHD syndrome and so need for colonoscopy surveillance. In the meantime we suggest that, in BHD families in which there is a history of colorectal neoplasia, colonoscopic screening should be offered to FLCN mutation carriers but, in view of the later age at onset of tumours, this could commence at age 45 years. -+  11  ---+  12  ---+  13  ---+  14  +  --+  15  ---+  16  ---+  17  --+  +  18  ---+  19  ---+  20  ---+  21  --+  +  22  ---+  23  +  --+  24  ---+  25  +  -+  +  26  ---+  27  -+  -+  28  +  --+  29  +  -+  +  30 --+ + 
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